Genetics Nurses Packaging Pharmacy 
The Pharma Data
JANUARY 16, 2021
” He pledged to ramp up vaccination availability in pharmacies, build mobile clinics to get vaccines to underserved rural and urban communities and encourage states to expand vaccine eligibility to people 65 and older, The New York Times reported. ” The vaccine distribution plan comes one day after Biden proposed a $1.9
The Pharma Data
DECEMBER 17, 2020
To develop this novel medicine, Regeneron scientists evaluated thousands of fully-human antibodies produced by the company’s VelocImmune ® mice, which have been genetically modified to have a human immune system, as well as antibodies identified from humans who have recovered from COVID-19.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
The Pharma Data
JANUARY 12, 2021
Nursing Mothers: There is currently no clinical experience in use of casirivimab and imdevimab injection in COVID-19 patients who are breastfeeding. Use in Specific Populations : Pregnancy: There is currently limited clinical experience in the use of casirivimab and imdevimab injection in COVID-19 patients who are pregnant.
The Pharma Data
DECEMBER 29, 2020
To develop this novel medicine, Regeneron scientists evaluated thousands of fully-human antibodies produced by the company’s VelocImmune ® mice, which have been genetically modified to have a human immune system, as well as antibodies identified from humans who have recovered from COVID-19.
The Pharma Data
NOVEMBER 20, 2020
To develop this novel medicine, Regeneron scientists evaluated thousands of fully-human antibodies produced by the company’s VelocImmune® mice, which have been genetically modified to have a human immune system, as well as antibodies identified from humans who have recovered from COVID-19. About Regeneron.
The Pharma Data
NOVEMBER 21, 2020
To develop REGEN-COV2, Regeneron scientists evaluated thousands of fully-human antibodies produced by the company’s VelocImmune ® mice, which have been genetically modified to have a human immune system, as well as antibodies identified from humans who have recovered from COVID-19.
XTalks
SEPTEMBER 14, 2020
CanSino Biologics is developing a vaccine that involves snipping a bit of the virus’ genetic code off and coupling it with a harmless virus to provoke a SARS-CoV-2 immune response. The package is made up of a €390 billion fund in grants and a €360 billion in low interest loans. And stimulus packages continue.
Expert insights. Personalized for you.
52 
Let's personalize your content